Some people are more likely to retain negative emotions than positive ones - as can happen with anxiety, depression of PTSD. (ESB Professional/Shutterstock)
New treatments for stress and anxiety may be possible after scientists worked out how the brain assigns positive or negative emotions to memories.
It may sound like the realms of science fiction, but an American research team has discovered a molecule in the brain responsible for associating good or bad feelings with a memory.
They say their findings, published in the journal Nature, pave the way for a better understanding of why some people are more likely to retain negative emotions than positive ones - as can happen with anxiety, depression or post-traumatic stress disorder (PTSD).
Senior author Professor Kay Tye, of the Salk Institute's Systems Neurobiology Laboratory, said: “We’ve basically gotten a handle on the fundamental biological process of how you can remember if something is good or bad.
“This is something that’s core to our experience of life, and the notion that it can boil down to a single molecule is incredibly exciting.”
She explained that for a human or animal to learn whether to avoid, or seek out, a particular experience again in the future, their brain must associate a positive or negative feeling - or “valence” - with that stimulus.
The brain’s ability to link these feelings with memories is called “valence assignment.”
In 2016, Prof Tye discovered that a group of neurons in the brain’s basolateral amygdala (BLA) helps assign valence when mice are learning.
One set of BLA neurons was activated with positive valence, as the animals learned to associate a tone with a sweet taste.
A separate set of BLA neurons was activated with negative valence, as the animals learned to associate a different tone with a bitter taste.
Prof Tye said: “We found these two pathways - analogous to railroad tracks - that were leading to positive and negative valence, but we still didn’t know what signal was acting as the switch operator to direct which track should be used at any given time."
In the latest study, Prof Tye's team homed in on the importance of the signaling molecule neurotensin to the BLA neurons.
They already knew that neurotensin is a neuropeptide produced by the cells associated with valence processing, but so are a few other neurotransmitters.
The team used CRISPR gene editing approaches to selectively remove the gene for neurotensin from the cells - the first time that CRISPR has been used to isolate specific neurotransmitter function.
Without neurotensin signaling in the BLA, Prof Tye explained that mice could no longer assign positive valence and didn’t learn to associate the first tone with a positive stimulus.
She said: "Interestingly, the absence of neurotensin did not block negative valence.
"The animals instead became even better at negative valence, having a stronger association between the second tone and a negative stimulus.
"The findings suggest that the brain’s default state is to have a bias toward fear - the neurons associated with negative valence are activated until neurotensin is released, switching on the neurons associated with positive valence."
From an evolutionary perspective, Prof Tye says it "makes sense" because it helps people avoid potentially dangerous situations -and it probably resonates with people who tend to find the worst in a situation.
In further experiments, Prof Tye and her team showed that high levels of neurotensin promoted reward learning and dampened negative valence, further supporting the idea that neurotensin is responsible for positive valence.
Co-first author Hao Li, a postdoctoral fellow in the Tye Lab, added: “We can actually manipulate this switch to turn on positive or negative learning.
“Ultimately, we’d like to try to identify novel therapeutic targets for this pathway.”
The researchers still have questions about whether levels of neurotensin can be modulated in people’s brains to treat anxiety or PTSD.
They are also planning future studies to probe what other brain pathways and molecules are responsible for triggering the release of neurotensin.
Stories and infographics by ‘Talker Research’ are available to download & ready to use. Stories and videos by ‘Talker News’ are managed by SWNS. To license content for editorial or commercial use and to see the full scope of SWNS content, please email [email protected] or submit an inquiry via our contact form.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.